Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or... INTRODUCTIONRadioimmunotherapy (RIT), a novel agent developed by binding a radioisotope to a monoclonal antibody, is considered a treatment option for radiation‐sensitive tumors.1,2 Previous studies investigating the efficacy of RIT showed promising results for B‐cell non‐Hodgkin's lymphoma (NHL).3,4 Based on previous studies, 90Y‐ibritumomab tiuxetan (90Y‐ibritumomab tiuxetan; Zevalin; Biogen Idec Inc., San Diego, CA, USA and Schering AG, Berlin, Germany) is currently approved for the treatment of relapsed or refractory follicular lymphoma and consolidation after primary treatment.5 We performed a phase II study of single administration and repeated therapy with 131I‐rituximab as salvage therapy in patients with relapsed or refractory B‐cell NHL.6,7 We have confirmed the efficacy and safety of 131I‐rituximab in a previous study.Among the subtypes of NHL, follicular lymphoma and mantle cell lymphoma are sensitive to radiotherapy. Therefore, for patients with stages I–II follicular lymphoma, 24–30 Gy involved site radiation therapy (ISRT) is the recommended standard treatment.8 In contrast, rituximab‐containing combination therapy is regarded as the first treatment in patients with follicular lymphoma stages III or IV who do not respond well to local control therapy.8 RIT is approved for relapsed or refractory follicular lymphoma and consolidation after primary treatment; however, the long‐term follow‐up data are problematic in few cases.8,9 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Download PDF
7 pages

Loading next page...
 
/lp/wiley/radioimmunotherapy-with-131i-rituximab-for-patients-with-relapsed-or-l8eynqufVy
Publisher
Wiley
Copyright
© 2023 John Wiley & Sons Australia, Ltd.
ISSN
1743-7555
eISSN
1743-7563
DOI
10.1111/ajco.13932
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONRadioimmunotherapy (RIT), a novel agent developed by binding a radioisotope to a monoclonal antibody, is considered a treatment option for radiation‐sensitive tumors.1,2 Previous studies investigating the efficacy of RIT showed promising results for B‐cell non‐Hodgkin's lymphoma (NHL).3,4 Based on previous studies, 90Y‐ibritumomab tiuxetan (90Y‐ibritumomab tiuxetan; Zevalin; Biogen Idec Inc., San Diego, CA, USA and Schering AG, Berlin, Germany) is currently approved for the treatment of relapsed or refractory follicular lymphoma and consolidation after primary treatment.5 We performed a phase II study of single administration and repeated therapy with 131I‐rituximab as salvage therapy in patients with relapsed or refractory B‐cell NHL.6,7 We have confirmed the efficacy and safety of 131I‐rituximab in a previous study.Among the subtypes of NHL, follicular lymphoma and mantle cell lymphoma are sensitive to radiotherapy. Therefore, for patients with stages I–II follicular lymphoma, 24–30 Gy involved site radiation therapy (ISRT) is the recommended standard treatment.8 In contrast, rituximab‐containing combination therapy is regarded as the first treatment in patients with follicular lymphoma stages III or IV who do not respond well to local control therapy.8 RIT is approved for relapsed or refractory follicular lymphoma and consolidation after primary treatment; however, the long‐term follow‐up data are problematic in few cases.8,9

Journal

Asia-Pacific Journal of Clinical Oncology – Wiley

Published: Mar 13, 2023

Keywords: 131I‐rituximab; follicular lymphoma; mantle cell lymphoma; phase II trial; radioimmunotherapy

References

  • Nuclear Medicine in Clinical Diagnosis and Treatment
    Chatal, JF; Mahé, M
  • Radiolabeled antibodies for cancer imaging and therapy
    Barbet, J; Bardiès, M; Bourgeois, M
  • Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B‐cell non‐Hodgkin lymphoma: updated results and long‐term follow‐up of the University of Michigan experience
    Kaminski, MS; Estes, J; Zasadny, KR
  • Radioimmunotherapy of relapsed indolent non‐Hodgkin lymphoma with 131I‐rituximab in routine clinical practice: 10‐year single‐institution experience of 142 consecutive patients
    Leahy, MF; Turner, JH
  • Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma
    Grillo‐López, AJ
  • Radioimmunotherapy with (131)I‐rituximab for patients with relapsed/refractory B‐cell non‐Hodgkin's lymphoma (NHL)
    Kang, HJ; Lee, SS; Kim, KM
  • Repeated radioimmunotherapy with 131I‐rituximab for patients with low‐grade and aggressive relapsed or refractory B cell non‐Hodgkin lymphoma
    Kang, HJ; Lee, SS; Byun, BH
  • Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up
    Dreyling, M; Ghielmini, M; Rule, S
  • Follicular lymphoma
    Carbone, A; Roulland, S; Gloghini, A
  • Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
    Yoon, DH; Cao, J; Chen, TY
  • Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    Ferrero, S; Pastore, A; Scholz, CW
  • Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group
    Cheson, BD; Horning, SJ; Coiffier, B
  • Pivotal study of iodine I 131 tositumomab for chemotherapy‐refractory low‐grade or transformed low‐grade B‐cell non‐Hodgkin's lymphomas
    Kaminski, MS; Zelenetz, AD; Press, OW
  • Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab‐refractory follicular non‐Hodgkin's lymphoma
    Witzig, TE; Flinn, IW; Gordon, LI
  • Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B‐cell lymphoma: long‐term follow‐up of a phase 1/2 study
    Gordon, LI; Molina, A; Witzig, T
  • Phase II study of yttrium‐90‐ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
    Wang, M; Oki, Y; Pro, B
  • Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions
    Zelenetz, AD; Noy, A; Pandit‐Taskar, N
  • Baseline SUVmax of 18F‐FDG PET‐CT indicates prognosis of extranodal natural killer/T‐cell lymphoma
    Xia, X; Wang, Y; Yuan, J
  • Maximum standard uptake value of 18F‐fluorodeoxyglucose positron emission tomography is a prognostic factor for progression‐free survival of newly diagnosed patients with diffuse large B cell lymphoma
    Miyazaki, Y; Nawa, Y; Miyagawa, M
  • Radioimmunotherapy with (131)I‐rituximab as consolidation therapy for patients with diffuse large B‐cell lymphoma
    Shin, DY; Byun, BH; Kim, KM
  • Radioimmunotherapy for mantle cell lymphoma: 5‐year follow‐up of 90 patients from the international RIT registry
    Hohloch, K; Windemuth‐Kieselbach, C; Zinzani, PL
  • Radioimmunotherapy (RIT) for follicular lymphoma achieves long term lymphoma control in first line and at relapse: 8‐year follow‐up data of 281 patients from the international RIT‐registry
    Hohloch, K; Windemuth‐Kieselbach, C; Kolz, J